Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take aim at Hard-to-Treat muscle disease

NCT ID NCT07715136

Recruiting now Disease control Sponsor: iCell Gene Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This phase 1 trial tests a new cell therapy called ICG318 CAR-T in adults with refractory inflammatory myopathy, a condition where the immune system attacks muscles, causing weakness and inflammation. The therapy uses a patient's own immune cells, engineered to target specific markers on harmful cells. The main goal is to check safety and find the right dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ICG318 CAR-T cells (BCMA-CD19-IL-15/IL-15 sushi compound CAR-T)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat inflammatory myopathy, potentially reducing symptoms and need for ongoing medication.
What could go wrong
This is an early, small phase 1 trial focused on safety, so it may not show clear benefit. CAR-T therapy carries risks like cytokine release syndrome and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

antisynthetase syndrome dermatomyositis idiopathic inflammatory myopathy immune-mediated necrotizing myopathy inclusion body myositis myositis disease polymyositis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATORY MYOPATHY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital, Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.